{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:47:24Z","timestamp":1785887244499,"version":"3.56.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009187","name":"Medical Research Foundation","doi-asserted-by":"publisher","award":["MRF-160-0019-ELP-EGGO-C0911"],"award-info":[{"award-number":["MRF-160-0019-ELP-EGGO-C0911"]}],"id":[{"id":"10.13039\/501100009187","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009187","name":"Medical Research Foundation","doi-asserted-by":"publisher","award":["MRF-160-0017-ELP-POUW-C0909"],"award-info":[{"award-number":["MRF-160-0017-ELP-POUW-C0909"]}],"id":[{"id":"10.13039\/501100009187","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009187","name":"Medical Research Foundation","doi-asserted-by":"publisher","award":["MRF-160-0019-ELP-EGGO-C0911"],"award-info":[{"award-number":["MRF-160-0019-ELP-EGGO-C0911"]}],"id":[{"id":"10.13039\/501100009187","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR207404"],"award-info":[{"award-number":["NIHR207404"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["222097\/Z\/20\/Z"],"award-info":[{"award-number":["222097\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/V015737\/1"],"award-info":[{"award-number":["MR\/V015737\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/X033260\/1"],"award-info":[{"award-number":["MR\/X033260\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>During the early phase of the COVID-19 pandemic in England, people with pre-existing conditions at severe clinical risk were advised to drastically reduce face-to-face contacts in a policy known as \u201cshielding\u201d. The impact of shielding in preventing COVID-19 hospitalisations and deaths has not been evaluated nationally using transmission-dynamic modelling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>With the approval of NHS England, we present a retrospective cohort evaluation of the shielding policy, drawing data from electronic health records (EHRs) for 24\u00a0million patients in England accessed through the OpenSAFELY platform. The study is from 1 January-1 December 2020, prior to vaccination and SARS-CoV-2 variants. We used a dynamic model of SARS-CoV-2 transmission, infection, and hospitalisation, stratified by age and shielding status for the general population (excluding care homes). We estimated transmission rates in the shielding and non-shielding groups using data from the CoMix social contact survey and fitted the model to hospitalisations and deaths in and outside hospital.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found the risk of hospitalisation was higher for shielding people at all ages and increased with age. The hospitalisation fatality risk was similar between shielding and non-shielding people from January to June 2020 and greater in shielding people from July 2020 onward. By comparing the observed epidemic to a counterfactual scenario without shielding, we projected that between 7800 and 10,600 hospitalisations and 2300 to 3500 deaths due to COVID-19 were directly averted by the policy, corresponding to reductions of 25% (24, 28%) and 23% (21, 25%), respectively, in the shielding population in England up to 1 December 2020. Including also the indirect effect in the non-shielding population, we projected 14,700\u2009\u2212\u200921,800 hospitalisations and 3700\u20135500 deaths due to COVID-19 were averted by the policy in the total population, each corresponding to reductions of 13% (11, 16%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Based on our data and assumptions, we estimated the shielding policy reduced severe illness and mortality in clinically-extremely vulnerable shielding patients in England up to 1 December 2020, and, through indirectly-reduced exposure, also in the non-shielding population. Similar policies for other infections could have a comparable public health impact in reducing both mortality and pressure on health services.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-026-04947-0","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T12:44:53Z","timestamp":1780058693000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of shielding on COVID-19 hospitalisations and deaths during 2020 in England: a transmission modelling evaluation using the OpenSAFELY platform"],"prefix":"10.1186","volume":"24","author":[{"given":"Johnny A. N.","family":"Filipe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alasdair","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas G","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Jarvis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen J","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen B","family":"Pouwels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W John","family":"Edmunds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"MacKenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seb","family":"Bacon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Mehrkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Goldacre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Tomlinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind M","family":"Eggo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"4947_CR1","unstructured":"National Audit Office. [shielding-start] Protecting and supporting the clinically extremely vulnerable during lockdown. 2021."},{"key":"4947_CR2","unstructured":"Government UK. Ministry of Housing, Communities and Local Government. [shielding-start2] Shielding clinically vulnerable people from COVID-19. 2020."},{"key":"4947_CR3","unstructured":"National Health Service England. Shielded Patient List. 2021."},{"key":"4947_CR4","unstructured":"Office for National Statistics. [ONS-shielding] Coronavirus and shielding of clinically extremely vulnerable people in England: 9 July to 16 July 2020. 2020."},{"key":"4947_CR5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jinf.2021.04.033","volume":"83","author":"A Zarif","year":"2021","unstructured":"Zarif A, Joy M, Sherlock J, Sheppard JP, Byford R, Akinyemi O, et al. The impact of primary care supported shielding on the risk of mortality in people vulnerable to COVID-19: English sentinel network matched cohort study. J Infect. 2021;83:228\u201336. https:\/\/doi.org\/10.1016\/j.jinf.2021.04.033.","journal-title":"J Infect"},{"key":"4947_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.puhe.2023.02.008","volume":"218","author":"H Snooks","year":"2023","unstructured":"Snooks H, Watkins A, Lyons J, Akbari A, Bailey R, Bethell L, et al. Did the UK\u2019s public health shielding policy protect the clinically extremely vulnerable during the COVID-19 pandemic in Wales? Results of EVITE Immunity, a linked data retrospective study. Public Health. 2023;218:12\u201320. https:\/\/doi.org\/10.1016\/j.puhe.2023.02.008.","journal-title":"Public Health"},{"key":"4947_CR7","doi-asserted-by":"publisher","first-page":"15278","DOI":"10.1038\/s41598-021-94630-6","volume":"11","author":"BD Jani","year":"2021","unstructured":"Jani BD, Ho FK, Lowe DJ, Traynor JP, MacBride-Stewart SP, Mark PB, et al. Comparison of COVID-19 outcomes among shielded and non-shielded populations. Sci Rep. 2021;11:15278. https:\/\/doi.org\/10.1038\/s41598-021-94630-6.","journal-title":"Sci Rep"},{"key":"4947_CR8","doi-asserted-by":"publisher","first-page":"105736","DOI":"10.1016\/j.puhe.2025.105736","volume":"244","author":"HA Snooks","year":"2025","unstructured":"Snooks HA, Akbari A, Bethell L, Carson-Stevens A, Dale J, Dixon L, et al. Evaluation of the UK\u2019s COVID-19 public health policy Shielding: Results of a linked data matched cohort study. Public Health. 2025;244:105736. https:\/\/doi.org\/10.1016\/j.puhe.2025.105736.","journal-title":"Public Health"},{"key":"4947_CR9","unstructured":"OpenSAFELY. [OpenSafely] Secure analytics platform for NHS electronic health records. 2025."},{"key":"4947_CR10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12916-020-01597-8","volume":"18","author":"CI Jarvis","year":"2020","unstructured":"Jarvis CI, Van Zandvoort K, Gimma A, Prem K, Auzenbergs M, O\u2019Reilly K, et al. Quantifying the impact of physical distance measures on the transmission of COVID-19 in the UK. BMC Med. 2020;18:124. https:\/\/doi.org\/10.1186\/s12916-020-01597-8.","journal-title":"BMC Med"},{"key":"4947_CR11","doi-asserted-by":"publisher","first-page":"e1003907","DOI":"10.1371\/journal.pmed.1003907","volume":"19","author":"A Gimma","year":"2022","unstructured":"Gimma A, Munday JD, Wong KLM, Coletti P, van Zandvoort K, Prem K, et al. Changes in social contacts in England during the COVID-19 pandemic between March 2020 and March 2021 as measured by the CoMix survey: A repeated cross-sectional study. PLOS Med. 2022;19:e1003907. https:\/\/doi.org\/10.1371\/journal.pmed.1003907.","journal-title":"PLOS Med"},{"key":"4947_CR12","unstructured":"Office for National Statistics. [ONS-England-mid-2020] Population estimates for the UK, England and Wales, Scotland and Northern Ireland: mid-2020. 2024."},{"key":"4947_CR13","unstructured":"OpenSAFELY. [OpenSafely-codelists] OpenCodelists. 2025."},{"key":"4947_CR14","doi-asserted-by":"publisher","first-page":"191","DOI":"10.12688\/wellcomeopenres.18010.1","volume":"7","author":"CD Andrews","year":"2022","unstructured":"Andrews CD, Schultze A, Curtis H, Hulme W, Tazare J, Evans S, et al. OpenSAFELY: Representativeness of electronic health record platform OpenSAFELY-TPP data compared to the population of England. Wellcome Open Res. 2022;7:191. https:\/\/doi.org\/10.12688\/wellcomeopenres.18010.1.","journal-title":"Wellcome Open Res"},{"key":"4947_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s11222-006-8769-1","volume":"16","author":"CJF Braak","year":"2006","unstructured":"Braak CJF. ter. A Markov Chain Monte Carlo version of the genetic algorithm Differential Evolution: easy Bayesian computing for real parameter spaces. Stat Comput. 2006;16:239\u201349. https:\/\/doi.org\/10.1007\/s11222-006-8769-1.","journal-title":"Stat Comput"},{"key":"4947_CR16","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11222-008-9104-9","volume":"18","author":"CJF ter Braak","year":"2008","unstructured":"ter Braak CJF, Vrugt JA. Differential Evolution Markov Chain with snooker updater and fewer chains. Stat Comput. 2008;18:435\u201346. https:\/\/doi.org\/10.1007\/s11222-008-9104-9.","journal-title":"Stat Comput"},{"key":"4947_CR17","doi-asserted-by":"publisher","unstructured":"Hartig F, Minunno F, Paul S, Cameron D, Ott T, Pichler M, BayesianTools. General-Purpose MCMC and SMC Samplers and Tools for Bayesian Statistics. 2023;version 0.1.8. https:\/\/doi.org\/10.32614\/CRAN.package.BayesianTools","DOI":"10.32614\/CRAN.package.BayesianTools"},{"key":"4947_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.epidem.2014.09.004","volume":"10","author":"D De Angelis","year":"2015","unstructured":"De Angelis D, Presanis AM, Birrell PJ, Tomba GS, House T. Four key challenges in infectious disease modelling using data from multiple sources. Epidemics. 2015;10:83\u20137. https:\/\/doi.org\/10.1016\/j.epidem.2014.09.004.","journal-title":"Epidemics"},{"key":"4947_CR19","doi-asserted-by":"publisher","DOI":"10.1201\/b16018","volume-title":"Bayesian data analysis. Third","author":"A Gelman","year":"2013","unstructured":"Gelman A, Carlin JB, Stern HS. Bayesian data analysis. Third. New York: Chapman and Hall\/CRC; 2013."},{"key":"4947_CR20","unstructured":"National Health Service England. [ONS-SPL-jul] Coronavirus Shielded Patient List Summary Totals, England - as at 9 July 2020. 2020."},{"key":"4947_CR21","unstructured":"National Health Service England. [ONS-SPL-oct] Coronavirus Shielded Patient List Summary Totals, England - as at 28 October 2020. 2020."},{"key":"4947_CR22","unstructured":"National Health Service England. [ONS-SPL-dec] Coronavirus Shielded Patient List Summary Totals, England - as at 3 December 2020. 2020."},{"key":"4947_CR23","unstructured":"UK Government, Department of Health & Social Care. [treatment-improved] Technical report on the COVID-19 pandemic in the UK, Chap. 10: improvements in care of COVID-19. 2023."},{"key":"4947_CR24","unstructured":"Office for Nationa Statistics. [ONS-England-mid-2020] Population estimates for the UK, England and Wales, Scotland and Northern Ireland: mid-2020. 2024."},{"key":"4947_CR25","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-020-0962-9","volume":"26","author":"NG Davies","year":"2020","unstructured":"Davies NG, Klepac P, Liu Y, Prem K, Jit M, Pearson CAB, et al. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat Med. 2020;26:1205\u201311. https:\/\/doi.org\/10.1038\/s41591-020-0962-9.","journal-title":"Nat Med"},{"key":"4947_CR26","doi-asserted-by":"publisher","first-page":"e375","DOI":"10.1016\/S2468-2667(20)30133-X","volume":"5","author":"NG Davies","year":"2020","unstructured":"Davies NG, Kucharski AJ, Eggo RM, Gimma A, Edmunds WJ, Jombart T, et al. Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study. Lancet Public Health. 2020;5:e375\u201385. https:\/\/doi.org\/10.1016\/S2468-2667(20)30133-X.","journal-title":"Lancet Public Health"},{"key":"4947_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s11222-006-8769-1","volume":"16","author":"CJF Braak","year":"2006","unstructured":"Braak CJF. ter. A Markov Chain Monte Carlo version of the genetic algorithm Differential Evolution: easy Bayesian computing for real parameter spaces. Stat Comput. 2006;16:239\u201349. https:\/\/doi.org\/10.1007\/s11222-006-8769-1.","journal-title":"Stat Comput"},{"key":"4947_CR28","doi-asserted-by":"publisher","first-page":"eabg4262","DOI":"10.1126\/scitranslmed.abg4262","volume":"13","author":"ES Knock","year":"2021","unstructured":"Knock ES, Whittles LK, Lees JA, Perez-Guzman PN, Verity R, FitzJohn RG, et al. Key epidemiological drivers and impact of interventions in the 2020 SARS-CoV-2 epidemic in England. Sci Transl Med. 2021;13:eabg4262. https:\/\/doi.org\/10.1126\/scitranslmed.abg4262.","journal-title":"Sci Transl Med"},{"key":"4947_CR29","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1177\/09622802211070257","volume":"31","author":"MJ Keeling","year":"2022","unstructured":"Keeling MJ, Dyson L, Guyver-Fletcher G, Holmes A, Semple MG, Tildesley MJ, et al. Fitting to the UK COVID-19 outbreak, short-term forecasts and estimating the reproductive number. Stat Methods Med Res. 2022;31:1716\u201337. https:\/\/doi.org\/10.1177\/09622802211070257.","journal-title":"Stat Methods Med Res"},{"key":"4947_CR30","doi-asserted-by":"publisher","first-page":"20200279","DOI":"10.1098\/rstb.2020.0279","volume":"376","author":"P Birrell","year":"2021","unstructured":"Birrell P, Blake J, Van Leeuwen E, Gent N, De Angelis D. Real-time nowcasting and forecasting of COVID-19 dynamics in England: the first wave. Philos Trans R Soc B Biol Sci. 2021;376:20200279. https:\/\/doi.org\/10.1098\/rstb.2020.0279.","journal-title":"Philos Trans R Soc B Biol Sci"},{"key":"4947_CR31","unstructured":"Google, Mobility."},{"key":"4947_CR32","unstructured":"https:\/\/www.visualcrossing.com\/. https:\/\/www.visualcrossing.com\/. https:\/\/www.visualcrossing.com\/"},{"key":"4947_CR33","doi-asserted-by":"publisher","unstructured":"Munday JD, Jarvis CI, Gimma, Amy L, van Zandvoort, Kevin S et al. [CoMix-zenodo] CoMix - Age structured contact matrices for 9 key periods of the COVID-19 epidemic in England (Version v1). 2021. https:\/\/doi.org\/10.5281\/zenodo.4677018","DOI":"10.5281\/zenodo.4677018"},{"key":"4947_CR34","unstructured":"Government UK. Ministry of Housing, Communities and Local Government. Shielding clinically vulnerable people from COVID-19. 2020."},{"key":"4947_CR35","doi-asserted-by":"publisher","unstructured":"Sullivan O, Gershuny JUKTUS, UK Time Diary StudyUnited. Kingdom Time Use SurveyUnited Kingdom Time Use Survey, 2014\u20132015. 2023. https:\/\/doi.org\/10.5255\/UKDA-SN-8128-1","DOI":"10.5255\/UKDA-SN-8128-1"},{"key":"4947_CR36","volume-title":"Handbook of Markov Chain Monte Carlo","year":"2011","unstructured":"Brooks S, Gelman A, Jones G, editors. Handbook of Markov Chain Monte Carlo. New York: Chapman and Hall\/CRC; 2011."},{"key":"4947_CR37","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12916-021-01982-x","volume":"19","author":"J Hellewell","year":"2021","unstructured":"Hellewell J, Russell TW, Matthews R, Severn A, Adam S, Enfield L, et al. Estimating the effectiveness of routine asymptomatic PCR testing at different frequencies for the detection of SARS-CoV-2 infections. BMC Med. 2021;19:106. https:\/\/doi.org\/10.1186\/s12916-021-01982-x.","journal-title":"BMC Med"},{"key":"4947_CR38","doi-asserted-by":"publisher","first-page":"7727","DOI":"10.1038\/s41467-022-35496-8","volume":"13","author":"D Chen","year":"2022","unstructured":"Chen D, Lau Y-C, Xu X-K, Wang L, Du Z, Tsang TK, et al. Inferring time-varying generation time, serial interval, and incubation period distributions for COVID-19. Nat Commun. 2022;13:7727. https:\/\/doi.org\/10.1038\/s41467-022-35496-8.","journal-title":"Nat Commun"},{"key":"4947_CR39","unstructured":"Office for National Statistics. [ONS-CIS-methods] Coronavirus (COVID-19) Infection Survey: methods and further information. 2023."},{"key":"4947_CR40","unstructured":"Office for National Statistics. [ONS-CIS-data] Coronavirus (COVID-19) Infection Survey: England. 2023."},{"key":"4947_CR41","unstructured":"Sero-. surveillance of COVID-19."},{"key":"4947_CR42","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s41512-022-00120-2","volume":"6","author":"EJ Williamson","year":"2022","unstructured":"Williamson EJ, Tazare J, Bhaskaran K, McDonald HI, Walker AJ, Tomlinson L, et al. Comparison of methods for predicting COVID-19-related death in the general population using the OpenSAFELY platform. Diagn Progn Res. 2022;6:6. https:\/\/doi.org\/10.1186\/s41512-022-00120-2.","journal-title":"Diagn Progn Res"},{"key":"4947_CR43","unstructured":"NHS England Digital. [NHS-digital-1] The NHS England OpenSAFELY COVID-19 service - privacy notice. 2023."},{"key":"4947_CR44","unstructured":"NHS England Digital. [NHS-digital-2] Data Security and Protection Toolkit. 2025."},{"key":"4947_CR45","unstructured":"NHS England Digital. [NHS-digital-3] ISB1523: Anonymisation Standard for Publishing Health and Social Care Data. 2022."},{"key":"4947_CR46","unstructured":"UK Government, Department of Health &. Social Care. [GOV-notice] [withdrawn] Coronavirus (COVID-19): notice under regulation 3(4) of the Health Service (Control of Patient Information) Regulations 2002 \u2013 general. 2022."},{"key":"4947_CR47","unstructured":"Secretary of State for Health and Social Care - UK Government. COVID-19 Public Health Directions 2020: notification to NHS Digital."},{"key":"4947_CR48","unstructured":"Health Research Authority. [HRA-confidentiality] Confidentiality Advisory Group. 2023."}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04947-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04947-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04947-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:02:17Z","timestamp":1785884537000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04947-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4947"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04947-0","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SB has received research funding from the Bennett Foundation, NHS England, the NIHR Oxford Biomedical Research Centre, the Wellcome Trust, XTX Markets, Health Data Research UK; he also receives personal income from consulting on digital healthcare with Respiratory Matters Ltd, and Madalena Consulting LLC. BG has received research funding from the Bennett Foundation, the Laura and John Arnold Foundation, the NHS National Institute for Health Research (NIHR), the NIHR School of Primary Care Research, NHS England, the NIHR Oxford Biomedical Research Centre, the Mohn-Westlake Foundation, NIHR Applied Research Collaboration Oxford and Thames Valley, the Wellcome Trust, the Good Thinking Foundation, Health Data Research UK, the Health Foundation, the World Health Organisation, UKRI MRC, Asthma UK, the British Lung Foundation, and the Longitudinal Health and Wellbeing strand of the National Core Studies programme; he has previously been a Non-Executive Director at NHS Digital; he also receives personal income from speaking and writing for lay audiences on the misuse of science. BMK is also employed by NHS England working on medicines policy and clinical lead for primary care medicines data. AM has represented the RCGP in the health informatics group and the Profession Advisory Group that advises on access to GP Data for Pandemic Planning and Research (GDPPR); the latter was a paid role. AM is a former employee and interim Chief Medical Officer of NHS Digital. AM has consulted for health care vendors, the last time in 2022; the companies consulted in the last 3 years have no relationship to OpenSAFELY.\u00a0AH reported receiving payments from Bayer for travel and consultancy after completion of this work, on an unrelated topic.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Health Research Authority (Research Ethics Committee reference 20\/LO\/0651) and by the London School of Hygiene & Tropical Medicine Ethics Board (reference 29468).","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NHS England is the data controller of the NHS England OpenSAFELY COVID-19 Service; TPP is the data processor; all study authors using OpenSAFELY have the approval of NHS England [\n                      \n                      ]. This implementation of OpenSAFELY is hosted within the TPP environment which is accredited to the ISO 27001 information security standard and is NHS IG Toolkit compliant [\n                      \n                      ]. Patient data has been pseudonymised for analysis and linkage using industry standard cryptographic hashing techniques; all pseudonymised datasets transmitted for linkage onto OpenSAFELY are encrypted; access to the NHS England OpenSAFELY COVID-19 service is18via a virtual private network (VPN) connection; the researchers hold contracts with NHS England and only access the platform to initiate database queries and statistical models; all database activity is logged; only aggregate statistical outputs leave the platform environment following best practice for anonymisation of results such as statistical disclosure control for low cell counts [\n                      \n                      ]. The service adheres to the obligations of the UK General Data Protection Regulation (UK GDPR) and the Data Protection Act 2018. The service previously operated under notices initially issued in February 2020 by the the Secretary of State under Regulation 3(4) of the Health Service (Control of Patient Information) Regulations 2002 (COPI Regulations), which required organisations to process confidential patient information for COVID-19 purposes; this set aside the requirement for patient consent [\n                      \n                      ]. As of 1 July 2023, the Secretary of State has requested that NHS England continue to operate the Service under the COVID-19 Directions 2020 [\n                      \n                      ]. In some cases of data sharing, the common law duty of confidence is met using, for example, patient consent or support from the Health Research Authority Confidentiality Advisory Group [\n                      \n                      ]. Taken together, these provide the legal bases to link patient datasets using the service. GP practices, which provide access to the primary care data, are required to share relevant health information to support the public health response to the pandemic, and have been informed of how the service operates.","order":4,"name":"Ethics","label":"Information governance and ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"415"}}